A rapid and sensitive LC-MS/MS method for determination of the active component K6 in serum of patients with depression

Lu, Dongyuan; Wanga, Zhipeng; Gao, Shouhong; Han, Yuehao; Wang, Hongsen; Li, Hanglin; Yan, Hongxia; Meng, Bosu; Mu, Yuhui; Jiang, Yi; Xia, Tao; Chen, Wansheng

doi:10.1016/j.jpba.2022.114691

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The methodology validation was completed according to FDA guidelines and Chinese Pharmacopoeia (2015 edition), and the linearity, inter- and intra-precision and accuracy, matrix effect and extraction recovery, stability and specificity of this method were validated according to previous study ( Lu et al, 2022 ; Wang et al, 2022 ; Shu et al, 2016 ).…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats

Sun,

Wang,

Liu

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

BackgroundTacrolimus (Tac) is commonly used for postoperative immunosuppressive therapy in transplant patients. However, problems, for example, low bioavailability and unstable plasma concentration, persist for a long time, Studies have reported that the deoxyschizandrin could effectively improve these problems, but the pharmacokinetic parameters (PKs) of Tac combined with deoxyschizandrin are still unknown.MethodIn this study, an UHPLC-MS/MS method has been established for simultaneous quantitation of Tac and deoxyschizandrin. The PKs of Tac influenced by different doses of deoxyschizandrin after single and multiple administrations were analyzed, and the different impact of deoxyschizandrin and Wuzhi capsule on PKs of Tac were compared.ResultThe modified UHPLC-MS/MS method could rapid quantification of Tac and deoxyschizandrin within 2 min using bifendatatum as the internal standard (IS). All items were successfully validated. The Cmax of deoxyschizandrin increased from 148.27 ± 23.20 to 229.13 ± 54.77 ng/mL in rats after multiple administrations for 12 days. After co-administration of 150 mg/mL deoxyschizandrin, Tac had an earlier Tmax and greater Cmax and AUC0–t, and the Cmax and AUC0–t of Tac increased from 14.26 ± 4.73 to 54.48 ± 14.37 ng/mL and from 95.10 ± 32.61 to 315.23 ± 92.22 h/ng/mL, respectively; this relationship was positively proportional to the dosage of deoxyschizandrin. In addition, compared with Wuzhi capsule, the same dose of deoxyschizandrin has a better effective on Tac along with more stable overall PKs.ConclusionAn UHPLC-MS/MS method was established and validated for simultaneous detection of deoxyschizandrin and Tac. Deoxyschizandrin could improve the in vivo exposure level and stability of Tac, besides, this effect is better than Wuzhi capsule in same dose.

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats

Sun,

Wang,

Liu

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The exclusion criteria mainly included the following: (1) subjects who had a suicide attempt within the last year, a currently significant risk of suicide, or a score ⩾3 points on Item 3 (suicide assessment) of the HAMD-17; (2) subjects with a current psychiatric diagnosis other than depression; (3) subjects with unstable cardiovascular, hepatic, renal, blood, endocrine, or other medical diseases; (4) subjects with any neurological disease (such as Parkinson's disease, cerebrovascular accident and epilepsy) or cerebral injury (traumatic or diseaserelated injury); (5) subjects with clinically significant abnormal laboratory values; (6) subjects who used at least two different antidepressants with the recommended dose and an adequate duration of treatment (maximum dosage for at least 4 weeks journals.sagepub.com/home/tpp TherapeuTic advances in psychopharmacology according to the label) and still had no response; (7) subjects who had received regular antidepressant treatment in the 2 weeks prior to screening; (8) subjects who received electroconvulsive therapy (ECT), transcranial magnetic stimulation, or other physical therapy within 3 months; (9) subjects who had a history of substance abuse (including alcohol, drug or other psychoactive substance abuse) within 1 year before screening; and (10) women who were pregnant, breastfeeding, or serum human chorionic gonadotropin (HCG) (+) on screening or were planning to become pregnant. A more detailed list of the inclusion/ exclusion criteria can be found at http://clinicaltrials.gov (NCT03183505).…”

Section: Patient Selectionmentioning

confidence: 99%

“…DC., a herb traditionally used in China for invigorating blood circulation and reducing detumescence, as well as for its analgesic properties. [6][7][8] A previous study showed that Piper laetispicum had antidepressant-like effects in an animal model of depression. [9][10][11] For example, Piper laetispicum could improve depression-like behavior by regulating inflammatory cytokines and apoptosis cytokines in chronic unpredictable mild stress (CUMS) model animals.…”

Section: Introductionmentioning

confidence: 99%

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults

He,

Yu,

Huang

et al. 2023

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Background: Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed. Objectives: This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD. Design: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study. Methods: A total of 172 patients with MDD from nine study centers were randomized (1:1) to receive placebo ( n = 86) or oral Anyu Peibo capsules (0.8 g) twice per day ( n = 86) for 6 weeks. The primary endpoint was the change in the Montgomery Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6, analyzed using an analysis of covariance (ANCOVA) approach with the baseline MADRS score, center effect and center by group interaction as the covariates. Other efficacy endpoints and variables included clinical response and remission rates according to the MADRS and the 17-item Hamilton Depression Rating Scale (HAMD-17) scores, the change in the HAMD-17, Clinical Global Impression – Severity scale and Clinical Global Impression – Improvement scale scores and the reduction in the Hamilton Anxiety Scale from baseline to week 6. Results: The mean baseline MADRS total scores were 29.20 and 29.72 in the Anyu Peibo ( n = 82) and placebo groups ( n = 81), respectively. The least squares mean change in the MADRS score from baseline to week 6 was 16.59 points in the Anyu Peibo group and 14.51 points in the placebo group. Although there were greater reductions in the MADRS score from baseline to week 6 in the Anyu Peibo capsule group compared to the placebo group, the difference did not reach statistical significance (least-squares mean difference, 2.07 points; 95% confidence interval, −0.27 to 4.41; p = 0.0819). The results of sensitivity analyses by ANCOVA with the last observation carried forward method for missing data indicated that the administration of Anyu Peibo capsules may lead to a significant reduction in depressive symptoms compared to the placebo (least-squares mean difference: 3.29 points; 95% confidence interval: 0.64–5.93; p = 0.0152). Furthermore, Anyu Peibo capsules showed significant benefits over placebo when the change in the HAMD-17 score from baseline to week 6 was evaluated as the secondary analysis ( t = 2.01; 95% confidence interval, 0.03–4.23; p = 0.0464). Conclusion: Anyu Peibo capsules may have an effective and safe antidepressant effect, which warrants further research.

show abstract

LC-MS/MS method for quantification of 23 TKIs in Plasma: Assessing the relationship between anlotinib trough concentration and toxicities

Bu,

Jiang,

Cui

et al. 2025

Clinica Chimica Acta

View full text Add to dashboard Cite

A rapid and sensitive LC-MS/MS method for determination of the active component K6 in serum of patients with depression

Cited by 4 publications

References 33 publications

Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats

Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults

LC-MS/MS method for quantification of 23 TKIs in Plasma: Assessing the relationship between anlotinib trough concentration and toxicities

Contact Info

Product

Resources

About